लोड हो रहा है...
Emerging therapies in advanced hepatocellular carcinoma
BACKGROUND: Prognosis is very poor for advanced HCC patients partially due to lack of effective systemic treatment. Sorafenib was the only approved agent for advanced HCC since 2007 until recent breakthroughs. In this article, we will review the newer approved and promising agents in the treatment o...
में बचाया:
| में प्रकाशित: | Exp Hematol Oncol |
|---|---|
| मुख्य लेखकों: | , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
BioMed Central
2018
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6076403/ https://ncbi.nlm.nih.gov/pubmed/30087805 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-018-0109-6 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|